Mark Harries

Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial

Andrew Tutt, Holly Tovey, Maggie C.U. Cheang et al. · Nature Medicine · 2018 · 903 citations · Full text

Medicine, Oncology, Pharmacology +11

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

David Miles, Joseph Gligorov, Fabrice André et al. · Annals of Oncology · 2021 · 729 citations · Full text

Medicine, Oncology, Pharmacology +17

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

Leticia Monin, Adam G. Laing, Miguel Muñoz‐Ruiz et al. · The Lancet Oncology · 2021 · 612 citations · Full text

Veterinary Medicine, Immunology, Oncology +14

Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma

Karla A. Lee, Andrew Maltez Thomas, Laura A. Bolte et al. · Nature Medicine · 2022 · 429 citations · Full text

Life Sciences, Immunology, Microbiology +17

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

Helena Earl, Louise Hiller, Anne-Laure Vallier et al. · The Lancet · 2019 · 283 citations · Full text

Medicine, Oncology, Pharmacotherapy +17